Using an anti-SFRP2 antibody, a clear vessel staining was also observed in tissue sections of angiosarcoma, prostate cancer, HCC, CRC, renal cell carcinoma, lung cancer, ovarian cancer, and pancreatic cancer [6, 98]. Here, SFRP2 is linked to ovarian carcinoma.